Research on Target Peptides and siRNA Delivery Systems in Lung Cancer Targeted Therapy
DOI:
https://doi.org/10.61173/nph4t706Keywords:
siRNA therapy, lung cancer, targeted peptides, treatment safety, nanoparticlesAbstract
With the development of gene silencing technology and siRNA, significant potential has been demonstrated in cancer treatment, garnering widespread attention. siRNA specifically targets and degrades certain mRNA, thereby inhibiting the expression of corresponding proteins. It has shown great promise in applications such as cancer, viral infections, and genetic diseases. However, the effective delivery of siRNA has been a major challenge for its clinical application. This paper focuses on discussing the mechanisms and advantages of siRNA delivery systems and introduces the current challenges and research issues faced by siRNA, such as the application mechanisms, dosage, and toxicity of targeted peptides and siRNA delivery systems.
References
through the RNA interference (RNAi) mechanism to [1] World Health Organization. (2023)Lung cancer. https:// silence disease-related genes. Designing the appro- www.who.int/news-room/fact-sheets/detail/lung-cancer?gad_ priate siRNA sequence is crucial for ensuring effec- source=1&gclid=Cj0KCQjw_qexBhCoARIsAFgBlevkqng tive gene silencing. h7TLL9Wx3RZ1-fHpUYX5i9Rsuc092t5rCqzyzBUZbM_ Construction of the Delivery System: It is generally g0o3EaAp3HEALw_wcB
necessary to construct a delivery carrier that can load [2] Siddique A., Otaibi F. M., Khan S. F. (2023)Handbook of both the targeting peptide and siRNA. Common car- Medical and Health Sciences in Developing Countries. Springer riers include lipid nanoparticles, polymer nanopar- publishing, The Berlin.
ticles, and others. The carrier needs to have good [3] Gao H., Liu J., Song N. (2014) Application of Target Peptide biocompatibility and sufficient protective properties in siRNA Delivery for the Research of Lung Cancer Therapy. to prevent the degradation of siRNA in the body. Chinese Journal of Lung Cancer, 17: 674–678. [4] Zhao G.,Ho W.Chu J.,Xiong X.,Hu B.,Boakye-Yiadom 4.1. Advantages of Combined Application of
K.O.,Xu X.,Zhang X.-Q.(2023) Inhalable siRNA Nanoparticles Target Peptides and siRNA Delivery Systems for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Targeting peptides are a class of small molecule pep- Non-Small-Cell Lung Cancer. ACS Appl, 31273-31284.
tides that can be used in conjunction with siRNA, [5] Kay, M. A., (2011) State-of-the-art gene-based therapies: the utilizing their specific binding to tumor surface sub- road ahead, Nature Reviews Genetics, vol. 12, no. 5, 316-328. stances to achieve targeted effects. By combining the [6] Wang, J., Tian, S., Petros, R. A., Napier, M. E., Desimone, J.
specificity of targeting peptides with the therapeutic M., (2010) The complex role of multivalency in nanoparticles action of siRNA, the accumulation of siRNA at the targeting the transferrin receptor for cancer therapies, Journal of target site is increased, enhancing the silencing ef- the American Chemical Society, vol. 132, no. 32, 11306-11313.
fect. This can improve the sensitivity of lung cancer [7] Wells, D. J., (2004)Gene therapy progress and prospects: to drugs and reduce resistance, thereby enhancing electroporation and other physical methods,” Gene Therapy, vol. the effectiveness of lung cancer treatment.[3] 11, no. 18, 1363-1369. 5.conclusion [8] Allen, T. M., Cullis, P. R., (2013) Liposomal drug delivery Research on targeting peptides and siRNA delivery sys- systems: from concept to clinical applications, Advanced Drug tems for lung cancer targeted therapy has improved sig- Delivery Reviews, vol. 65, no. 1, 36-48.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
